These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26346493)

  • 1. Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
    Ashford AL; Dunkley TP; Cockerill M; Rowlinson RA; Baak LM; Gallo R; Balmanno K; Goodwin LM; Ward RA; Lochhead PA; Guichard S; Hudson K; Cook SJ
    Cell Mol Life Sci; 2016 Feb; 73(4):883-900. PubMed ID: 26346493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
    Abu Jhaisha S; Widowati EW; Kii I; Sonamoto R; Knapp S; Papadopoulos C; Becker W
    Sci Rep; 2017 Jul; 7(1):6420. PubMed ID: 28743892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
    Leder S; Czajkowska H; Maenz B; De Graaf K; Barthel A; Joost HG; Becker W
    Biochem J; 2003 Jun; 372(Pt 3):881-8. PubMed ID: 12633499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).
    Ashford AL; Oxley D; Kettle J; Hudson K; Guichard S; Cook SJ; Lochhead PA
    Biochem J; 2014 Jan; 457(1):43-56. PubMed ID: 24134204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of dual specificity kinase activity of DYRK1A.
    Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
    FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of two DYRK1B variants causative of AOMS3.
    Detro-Dassen S; Sternberg A; Lehmann SM; Schwandt K; Düsterhöft S; Becker W
    Orphanet J Rare Dis; 2024 Jun; 19(1):233. PubMed ID: 38867326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
    Schramek H; Feifel E; Healy E; Pollack V
    J Biol Chem; 1997 Apr; 272(17):11426-33. PubMed ID: 9111053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mek1 phosphorylation site mutants activate Raf-1 in NIH 3T3 cells.
    Alessandrini A; Greulich H; Huang W; Erikson RL
    J Biol Chem; 1996 Dec; 271(49):31612-8. PubMed ID: 8940180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.
    Papenfuss M; Lützow S; Wilms G; Babendreyer A; Flaßhoff M; Kunick C; Becker W
    Sci Rep; 2022 Feb; 12(1):2393. PubMed ID: 35165364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases.
    Zheng CF; Guan KL
    J Biol Chem; 1993 Nov; 268(32):23933-9. PubMed ID: 8226933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase.
    Oh-hora M; Ogata M; Mori Y; Adachi M; Imai K; Kosugi A; Hamaoka T
    J Immunol; 1999 Aug; 163(3):1282-8. PubMed ID: 10415025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways.
    Kamiguti AS; Harris RJ; Slupsky JR; Baker PK; Cawley JC; Zuzel M
    Oncogene; 2003 Apr; 22(15):2272-84. PubMed ID: 12700663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of active MEK1-ERK1/2 restores epithelial phenotype and morphogenesis in transdifferentiated MDCK cells.
    Schramek H; Feifel E; Marschitz I; Golochtchapova N; Gstraunthaler G; Montesano R
    Am J Physiol Cell Physiol; 2003 Sep; 285(3):C652-61. PubMed ID: 12900389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simian virus 40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity.
    Frost JA; Alberts AS; Sontag E; Guan K; Mumby MC; Feramisco JR
    Mol Cell Biol; 1994 Sep; 14(9):6244-52. PubMed ID: 8065356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
    Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
    Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes.
    Xiao L; Pimental DR; Amin JK; Singh K; Sawyer DB; Colucci WS
    J Mol Cell Cardiol; 2001 Apr; 33(4):779-87. PubMed ID: 11273730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway.
    Ehses JA; Pelech SL; Pederson RA; McIntosh CH
    J Biol Chem; 2002 Oct; 277(40):37088-97. PubMed ID: 12138104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.
    Brichkina A; Ems M; Suezov R; Singh R; Lutz V; Picard FSR; Nist A; Stiewe T; Graumann J; Daude M; Diederich WE; Finkernagel F; Chung HR; Bartsch DK; Roth K; Keber C; Denkert C; Huber M; Gress TM; Lauth M
    Gut; 2024 Sep; 73(10):1684-1701. PubMed ID: 38834297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2.
    Butch ER; Guan KL
    J Biol Chem; 1996 Feb; 271(8):4230-5. PubMed ID: 8626767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.